نتائج البحث 71-80 من 23760 لعملية البحث عن Treatment
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer.
... treatment in patients with treatment-naive ALK-positive advanced NSCLC. Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg ...
The purpose of this study is to explore various biomarkers in the post-treatment tissue of patients who have responded to cancer therapy and compare it to ...
... treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2 ... treatment, post-treatment and (when available) post-mortem soft tissue ...
... treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of ...
Tafasitamab, Lenalidomide And Venetoclax For The Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma. Rochester, Minn. The purpose of this study is to ...
(Z)-Endoxifen For The Treatment Of Premenopausal Women With ER+/HER2- Breast Cancer. Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn. This ...
... treatment of patients with chronic myelomonocytic leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Onvansertib is ...
Treatment options are then defined according to the disease burden strata. Treatment is allocated by randomisation. Patients may be allocated to one of ...
Patients may receive a single dose to a liver lobe or segmental treatment delivered as a sequence of treatments approximately 30-90 days apart. The ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.